Shire PLC (SHPG-Q) Stock Predictions - Stockchase
WATCH LIST
6
Shire PLC (SHPG-Q)

ON STOCKCHASE SINCE Jan 2006

biotechnology/pharmaceutical

Shire PLC

SHPG-Q

1 watching          
Join the Discussion

Shire PLC (SHPG-Q) SAVE Apr, 18, 2019, 9:21 pm

179.20 0 (0%)

About Shire PLC (SHPG-Q)

Shire Plc is a Jersey-registered, Irish-headquartered global specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products include Vyvanse, Lialda, and Adderall XR. More at Wikipedia

What the experts are saying about SHPG-Q



  • All
  • Filtered
Signal Opinion Expert
TOP PICK
Shire PLC(SHPG-Q) 

April 18, 2017

A pharmaceutical/biotech company. It has an extremely attractive valuation, dirt cheap, trading at under 11X forward earnings. This has a really good stable of rare disease drugs that are very much untouched in the marketplace. The pharmaceutical sector has been absolutely beaten up and is becoming absolutely compelling. Dividend yield of 0.53%. (Analysts’ price target is £6100.)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

A pharmaceutical/biotech company. It has an extremely attractive valuation, dirt cheap, trading at under 11X forward earnings. This has a really good stable of rare disease drugs that are very much untouched in the marketplace. The pharmaceutical sector has been absolutely beaten up and is becoming absolutely compelling. Dividend yield of 0.53%. (Analysts’ price target is £6100.)

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
John Stephenson

President , Stephenson & Company...

Price Price
$169.640
Owned Owned
Yes

BUY
Shire PLC(SHPG-Q) 

May 25, 2016

(Market Call Minute) He likes pharma and the more North American focus.  Prefers JNJ-N but is okay with this one.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(Market Call Minute) He likes pharma and the more North American focus.  Prefers JNJ-N but is okay with this one.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$191.780
Owned Owned
Unknown

PAST TOP PICK
Shire PLC(SHPG-Q) 

February 4, 2013

(A Top Pick Feb 1/12. Up 2.18%.) Focused on special opportunities in the pharmaceutical world. Got under pressure because there were generics coming in on their key drugs but it turned out the risk wasn’t as threatening as the market had expected. Stock has been rallying lately.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Feb 1/12. Up 2.18%.) Focused on special opportunities in the pharmaceutical world. Got under pressure because there were generics coming in on their key drugs but it turned out the risk wasn’t as threatening as the market had expected. Stock has been rallying lately.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ian Ainsworth

Vice Presi, MacKenzie Financial ...

Price Price
$101.400
Owned Owned
Yes

TOP PICK
Shire PLC(SHPG-Q) 

February 1, 2012

Irish pharmaceutical company and its major franchise is Adderall for attention deficit disorder. The opportunity here is that they can move it into adults. The other part of their business is orphan drugs, drugs that are not targets for large pharmaceuticals.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Irish pharmaceutical company and its major franchise is Adderall for attention deficit disorder. The opportunity here is that they can move it into adults. The other part of their business is orphan drugs, drugs that are not targets for large pharmaceuticals.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ian Ainsworth

Vice Presi, MacKenzie Financial ...

Price Price
$99.640
Owned Owned
Yes

TOP PICK
Shire PLC(SHPG-Q) 

November 9, 2006

(A Top Pick Jan 26/05. Up 11%.) Pharma company that’s moving into the biotech space. Have a lot of new products. Does $1.9 billion in revenues and can add another $1.4 billion incremental revenues in the next 4-5 years if the products are approved.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Jan 26/05. Up 11%.) Pharma company that’s moving into the biotech space. Have a lot of new products. Does $1.9 billion in revenues and can add another $1.4 billion incremental revenues in the next 4-5 years if the products are approved.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ian Ainsworth

Vice Presi, MacKenzie Financial ...

Price Price
$56.140
Owned Owned
No

TOP PICK
Shire PLC(SHPG-Q) 

January 26, 2006

A UK company that does such nervous system pharmaceutical products. The big product is for hyperactive disorder. Adderall, a big seller, does not become generic for three years. Multiple in the high teens. Also has five new products coming out.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
A UK company that does such nervous system pharmaceutical products. The big product is for hyperactive disorder. Adderall, a big seller, does not become generic for three years. Multiple in the high teens. Also has five new products coming out.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ian Ainsworth

Vice Presi, MacKenzie Financial ...

Price Price
$47.630
Owned Owned
Yes

Showing 1 to 6 of 6 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days